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Abstract 
Bone implants with open porosity enable fast osseointegration, but also present an increased 
risk of biofilm-associated infections. We design a novel implant material consisting of a 
mesoporous SiO2 diffusion barrier (pore diameter: 6.4 nm) with controlled drug release 
functionality integrated in a macroporous Ti load-bearing structure (fully interconnected open 
porosity: 30%; pore window size: 0.5 to 2.0 µm). Using an in vitro tool consisting of Ti/SiO2 
disks in an insert set-up, through which molecules can diffuse from feed side to release side, a 
continuous release without initial burst effect of the antibiofilm compound toremifene is 
sustained for at least 9 days, while release concentrations (up to 17 µM daily) increase with 
feed concentrations (up to 4 mM). Toremifene diffusivity through the SiO2 phase into H2O is 
estimated around 10
-13
 m²/s, suggesting configurational diffusion through mesopores. 
Candida albicans biofilm growth on the toremifene-release side is significantly inhibited, 
establishing a proof-of-concept for the drug delivery functionality of mesoporous SiO2 
incorporated into a high-strength macroporous Ti carrier. Next-generation implants made of 
this composite material and equipped with an internal reservoir (feed side) can yield long-
term controlled release of antibiofilm compounds, effectively treating infections on the 
implant surface (release side) over a prolonged time. 
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1. Introduction 
The increased spread of implant expertise together with the expansion of a lifestyle-aware 
ageing population is driving the demand for orthopedic and dental implants, resulting in 
extensive growth rates of the implant market [1]. This, however, also means that the rather 
small failure rates of implantation turn into huge economic concerns. Unless failure rates are 
significantly reduced, the incidence of implant failure will rise, burdening both patients and 
health care systems.  
The occurrence of peri-implant infections are a devastating complication which often takes 
years to develop, but may ultimately lead to progressive bone loss, resulting in implant 
instability and even replacement of the implant with a high risk of recidivism [2]. The 
infection risk for primary hip and knee replacements is around 1%, which increases to 2-5% 
for revision surgeries [3–5]. For dental implants, the prevalence of peri-implantitis even rises 
up to 10%, typically occurring 5-10 years after implant placement and related primarily to 
bacterial plaque accumulation owing to insufficient plaque removal by the patient or to poorly 
fitting implant components acting as anchoring sites for bacteria [6]. The occurrence of early 
infections can be the consequence of an insufficiently sterile environment during surgery and 
can also lead to the need for implant revision [7,8]. Therefore, the use of peri-operative 
antimicrobial compounds might be recommended, especially when proper asepsis cannot be 
assured or in case of a medically compromised patient. 
Since an implant, as a biocompatible surface, presents a favorable support for microbial 
adherence and because the local immune system is temporarily repressed at the implant/tissue 
interface due to the occurrence of a foreign body response, the implantation site is inherently 
at risk for microbial contamination [2,9]. In addition, microorganisms instigating these 
infections typically form aggregates of adherent cells embedded within a self-produced matrix 
of extracellular polymeric substance, so called biofilms [10–12]. Within this protective 
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environment, bacteria or fungi are considerably less susceptible to host immune defenses and 
antimicrobial agents. This increased tolerance of microbial biofilm cells is due to the 
induction of specific resistance mechanisms, poor antibiotic penetration and lack of active 
growth of cells within the biofilm [13,14]. Although a systemic administration of antibiotics 
can control the acute phases of infection, it is not effective in eliminating the biofilm 
completely [11]. 
Current strategies regarding infection-resistant materials aim at the development of anti-
adhesive surfaces (passive coatings), such as anatase TiO2 and hydrophilic poly(methacrylic 
acid), and/or carrier materials for the local delivery of antimicrobial substances (active 
coatings), such as biodegradable polymers or porous materials loaded with antibiotics or 
metal ions [3,4,15,16]. Although the preventive approach of anti-adhesive surfaces appears 
promising, its effectiveness is limited due to the formation of an adsorbed conditioning film 
on the surface [17]. When microorganisms do adhere and form biofilms, localized drug 
delivery directly targeting the implant site for a prolonged period of time is preferable. This 
has several advantages over a systemic drug delivery, such as better control over toxicity and 
bioavailability of the dose and avoidance of systemic drug exposure. Moreover, new 
strategies aiming at an extended duration of drug release directly to site are recommended 
[18]. 
Therefore, implants harboring an accessible internal reservoir (feed side) containing, e.g. 
antibiofilm agents and made of composite materials, combining the load-bearing strength of a 
metallic matrix with the tunable release kinetics of a high-surface area drug carrier material in 
the bulk of the metal, are a promising anti-infective strategy to bring the metal-based drug 
eluting systems for bone implants to a clinical level. Ordered mesoporous and microporous 
silica materials are widely investigated as drug delivery systems due to their stability and 
biocompatibility in combination with a high surface area and large pore volume available for 
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drug adsorption/encapsulation [19,20]. Moreover, these materials are marked by a relatively 
easy synthesis with extensive control over the pore morphology and/or chemistry and as such 
also the drug release kinetics. The controlled release of several therapeutic drug molecules 
including antimicrobial compounds has been verified [21–25]. Up to now, very limited 
attention has been devoted to the application of drug delivery vehicles in the bulk of metallic 
implants. For example, porous titanium (Ti) or stainless steel cylinders have been described to 
serve as a reservoir for drug loaded gelatin sponges or packed beds of mesoporous silica 
particles, respectively [26–28]. Moreover, we have previously synthesized amorphous 
microporous silica inside an open porous Ti surface coating for the controlled release of 
chlorhexidine [29]. This inspired us to the idea of incorporating a mesoporous diffusion 
barrier, consisting of SiO2, in a bulk porous Ti implant material for the controlled release of a 
therapeutic compound from an internal reservoir. We hypothesize that, in contrast to a 
localized drug delivery from a porous surface coating which has to be saturated with the 
compound prior to implantation, the current design will allow avoiding an initial burst release 
as well as a premature depletion of the compound, so that the release concentration can be 
more readily fine-tuned within the narrow window above the minimum (biofilm) inhibitory 
concentration and below the cytotoxicity level for a longer period of time.  
In the present study, we first report on the development of a Ti/SiO2 composite material 
together with an in vitro test tool consisting of Ti/SiO2 disks inserted in a 12-well microplate, 
for assessing the activity of antibiofilm compounds released from the feed side through the 
Ti/SiO2 disks to the release side. A proof-of-concept is established using toremifene as a 
broad-spectrum antibiofilm molecule. It has reported activity against the formation of 
biofilms of human pathogenic yeasts like Candida albicans [30, 31] and bacterial pathogens 
like Pseudomonas aeruginosa, Escherichia coli, Staphylococcus epidermidis, Staphylococcus 
aureus [31] and Porphyromonas gingivalis (Jan Michiels, unpublished data), which was 
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recently confirmed in vivo for C. albicans and S. aureus [31]. All these pathogenic species are 
known to form biofilms on medical devices and implants [32–37]. 
 
2. Materials and methods 
2.1 Ti/SiO2 substrate preparation 
As a macroporous carrier material, Ti substrates with interconnected porosity within the 
micrometer size range were envisaged. Disk shaped pure Ti substrates (Ø 12.2 mm, h=1.3 
mm) with a macroporosity were obtained by a powder metallurgical processing route. As 
starting powders, a Ti (grade S < 8 µm, min. 98.7% Ti, Rockwood Lithium) and a TiH2 
powder (grade VM, min. 94% Ti and min. 3.7% H, Rockwood Lithium) produced by a 
hydration-dehydration (HDH) treatment were used. Prior to sample preparation, the particle 
size was analyzed by scanning electron microscope (SEM, XL30 FEG, FEI) and laser 
diffraction (Mastersizer MicroPlus, Malvern). Next, a 90:10 molar mixture of Ti and TiH2 
powders was prepared by dry mixing in a multidirectional mixer (Turbula T2C) under Ar for 
24 h. This powder was pressed into pellets of 0.5 g using a hardened steel die at 50 kN. 
Subsequently, the disks were dehydrogenated and sintered by resistive heating in a high 
vacuum furnace (10
-6
 mbar). To complete dehydrogenation of the TiH2, the samples were 
stepwise heated at 5°C/min to 450°C (dwell time 1 h), further at 2°C/min to 550°C (dwell 
time 1 h), at 2°C/min to 650°C (dwell time 1 h), followed by heating at 10°C/min to the 
sintering temperature at 850°C (dwell time 5 min) in order to consolidate the powder particles 
and allow partial densification of the structure. Afterwards, the samples were allowed to cool 
down passively in the furnace.  
For preparing the mesoporous diffusion barrier, a 40 wt% colloidal SiO2 suspension in H2O 
(Ludox® HS-40, Sigma-Aldrich) and a 0.055 M HCl (37%, Chemlab) solution in 
demineralized H2O were mixed (1:1 volume) and magnetically stirred for 10 min. Next, the 
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sol was injected through the Ti disks using a high pressure pump (880-PU, Jasco) at a flow 
rate of 10 mL/min until the sol could be recovered on the other side. In order to ensure 
complete filling at the edges, an in-house designed sample holder which allowed gripping of 
the porous Ti disks at the edge was applied. Afterwards, samples were allowed to age 
overnight at 60°C (Binder, VWR). The impregnation process was repeated twice in order to 
compensate for shrinkage effects. Finally, samples were calcined in air for 6 h at 225°C 
applying a heating rate 1°C/min (RHF 1200, Carbolite Furnaces). 
 
2.2 Material characterization 
Polished cross-sections of pure Ti and Ti/SiO2 were examined by SEM (Nova NanoSEM 450, 
FEI) with associated energy dispersive X-ray spectroscopy (EDX, EDAX). The 
metallographic cross-sections were prepared as follows: samples were embedded in epoxy 
resin (EpoxyCure, Buehler) while applying a low vacuum to ensure a good penetration of the 
resin in the pores, next samples were cut using a Secotom-10 sawing machine (Struers) with a 
10S20 sawing blade (Struers), finally cross-sections were ground using 1200 and 4000 grit 
SiC papers (Hermes) and polished with a 3 µm and 1 µm diamond suspension (3-WM and 1-
WM, Kemet) applying an automatic polishing machine (Pressair TF250, Jean Wirtz). Pore 
characteristics of the porous Ti compacts prior to SiO2 impregnation were determined by 
image analysis of SEM images and Hg intrusion porosimetry (MIP, AutoPore IV 9500, 
Micromeretics). Reported values are an average of multiple point measurements on 3 
samples. As quality control of the SiO2 filling degree, the air flow rate (at 3 bar) through Ti 
discs before and after SiO2 impregnation was measured using a digital flow meter (SAGA 
DFM 5000, Ion Science). The mesoporosity of the Ti/SiO2 composites after impregnation was 
characterized by nitrogen adsorption/desorption at -196°C (Autosorb 1, Quantachrome). Prior 
to measurement, samples were evacuated at 200°C for 12 h under vacuum. The specific 
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surface area was evaluated using the BET method, while the pore size distribution was 
determined using the DFT method on the adsorption branch of the isotherm. Reported values 
are an average of 4 samples. 
 
2.3 Construction of the in vitro test tool 
An in vitro test tool was constructed using the Ti/SiO2 disks in a 12-well plate setup as a 
model for implants with internal reservoir. To this end, twelve-well plates with polystyrene 
cell culture inserts (Transwell®) were purchased from Corning Incorporated (Corning, NY, 
USA). The permeable membrane of the inserts (Ø 12.2 mm) was removed and the 
experimental Ti/SiO2 disks were fitted into the inner opening (figure 1a). In order to seal the 
interstice in-between the Ti/SiO2 disk and polystyrene cup, inserts were locally heated above 
the glass transition temperature of polystyrene (~100°C) to soften the polymer while 
squeezing it radially around the disks. A leakage test using an aqueous methylene blue (96%, 
Acros Organics) solution confirmed successful sealing as the dye did not penetrate in-between 
the Ti/SiO2 disk and the polystyrene cup. 
 
2.4 Strains and chemicals for release experiments 
The Candida albicans strain SC5314 [38], used in this study was grown routinely on YPD 
(1% yeast extract, 2% peptone (International Medical Products, Belgium) and 2% glucose 
(Sigma-Aldrich, MO, USA)) agar plates at 30°C for two days. Stock solutions of toremifene 
citrate (PubChem CID 3005572; TCI Europe, Belgium) were prepared in DMSO (VWR 
International, PA, USA). RPMI 1640 medium (pH 7.0) with L-glutamine and without sodium 
bicarbonate was purchased from Sigma-Aldrich and buffered with MOPS (Sigma-Aldrich). 
Phosphate buffered saline (PBS) constituted of 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4 
and 0.24 g/L KH2PO4 (pH 7.4; VWR International).  
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The size of toremifene was determined by generating a 3D model of the molecule and 
measuring the interatomic distances at its extremities using the Marvin package (version 
6.2.2) from ChemAxon (http://www.chemaxon.com). 
 
2.5 Toremifene release experiments 
Milli-Q water (MQ) solutions (termed ‘feed’) containing different concentrations of 
toremifene (0, 2, 3 and 4 mM in 2% DMSO), were supplied to 12-well plates (1.4 mL/well, 4-
9 wells/condition). Ti/SiO2 disks sealed into polystyrene cups were decontaminated with 
100% EtOH (VWR International, USA), dried under sterile conditions and placed in the 
wells, assuring contact between disk and feed solution. On the release side of the Ti/SiO2 
disk, 300 μL MQ was pipetted, after which the plates were placed in a humidified box to 
avoid evaporation of the feed and release solutions. The release sample was replaced after 2 
days and daily thereafter to maintain sink conditions (figure 1b). Toremifene release at 37°C 
from the feed side to the release side of the Ti/SiO2 disk was measured in 100 μL of the 
release sample by UV spectrophotometry (in UV Star microplates (Greiner Bio-One GmbH, 
Germany) with a Synergy Mx multi-mode microplate reader (Biotek)) and release 
concentrations were calculated based on a calibration curve which was established on 
beforehand. To this end, a series of solutions containing 1-50 μM toremifene in 0, 1 and 2% 
DMSO was prepared. The UV absorbance of 100 µl of each suspension was measured, 
confirming (i) the absorption peak of toremifene at 278 nm [39], (ii) that absorption was 
independent of the DMSO background and (iii) a linear relationship between absorbance at 
278 nm and toremifene concentration over the entire concentration range that was tested 
(R²=0.997).  
 
 
10 
 
2.6 Candida albicans biofilm growth assay 
After 10 days of toremifene release through the Ti/SiO2 disks in the above described release 
experiments, the release sample was replaced by 300 μL fetal bovine serum (Perbio Science, 
Belgium) and plates were incubated for 1 h at 37°C. Subsequently, Ti/SiO2 disks were washed 
with 300 μL MQ and 300 μL RPMI medium containing 104 C. albicans cells/mL was applied 
on the release site. Biofilms of C. albicans were allowed to grow on the release side of the 
Ti/SiO2 disks for 72 h at 37°C (renewal of RPMI after 48 h), washed with PBS and quantified 
with the viability dye CellTiter-Blue® (CTB) [40] by adding 300 µL CTB diluted 1/10 in 
PBS to each well. After 2 h of incubation in the dark at 37°C, fluorescence was measured 
with a fluorescence spectrometer (Synergy Mx multi-mode microplate reader (Biotek)) at an 
excitation wavelength of 535 nm and an emission wavelength of 590 nm. Fluorescence values 
of the samples were corrected by subtracting the average fluorescence value of CTB of 
uninoculated wells (blank). Percentage of metabolically active biofilm cells was calculated 
relative to the control treatment (feed solution of 2% DMSO). Results were analyzed for 
statistical significance by unpaired student's t test. 
 
3. Results 
3.1 Physicochemical characterization of the Ti/SiO2 composites 
The Ti powder had a particle size distribution with a D10 diameter of 3.8 µm, a D50 diameter 
of 10.7 µm and a D90 diameter of 45.2 µm, whereas for the TiH2 powder size D10 was 3.3 
µm, D50 7.4 µm and D90 15.2 µm. These results are consistent with the SEM micrographs 
revealing angular fine (<10 µm) powder particles for both powders, but with a considerable 
amount of larger chunks for the Ti powder (figure 2a-b). The powder angularity, and the 
presence of large particles, is also reflected in the pore structure of the Ti disks after sintering 
(figure 2c). The total porosity measured by image analysis amounted 29.0 ± 0.9%, while the 
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open porosity as measured by mercury intrusion porosimetry (MIP) was 29.8 ± 1.1%. The 
interconnecting pore window size distribution, represented as the differential intrusion volume 
as function of pore window size, after sintering is given in figure 2d. The pore window size 
ranges from 0.5 to 2.0 µm with an average pore size of 1.5 ± 0.2 µm.  
After SiO2 impregnation, a qualitative investigation of the filling degree was performed by 
SEM imaging of a polished cross-section of a Ti/SiO2 composite after calcination. Figure 3a 
shows a SEM micrograph with associated EDX mappings for Ti, Si and O. It can be seen that 
the pores of the Ti structure are largely filled up by SiO2. A higher magnification of the 
Ti/SiO2 interface is given in Figure 3b, this shows a good contact between the Ti and the SiO2 
phase without large voids in-between. In addition, the air flow rate (at 3 bar) reduced from 
over 1500 mL/min to 30 ± 12 mL/min after SiO2 impregnation, confirming the presence of a 
SiO2 diffusion barrier without interconnected macropores throughout the thickness of the 
discs. 
The mesoporous structure of the produced Ti/SiO2 disks was characterized by nitrogen 
adsorption. A representative nitrogen adsorption/desorption isotherm of the calcined material 
is shown in figure 4a. All samples exhibited a type IV isotherm, featuring a hysteresis loop 
due to the presence of mesopores. The monomodal pore size distribution, given in figure 4b, 
is narrow with a mean pore diameter of approximately 6.4 ± 0.6 nm. The specific surface area 
was 144 ± 8 m²/g, as determined using the BET-method. 
 
3.2 In vitro release experiments 
Preliminary experiments to monitor release of a compound through the Ti/SiO2 material were 
performed with the dye methylene blue (50 mM as feed solution) and demineralized water at 
the release side of the in vitro test tool, revealing a lag phase before detection of methylene 
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blue at the release side. UV-spectroscopy (at 630 nm) of the release samples showed a 
continuous release of methylene blue over 10 days after the lag phase (results not shown). 
Based on these observations, different feed concentrations of toremifene (0, 2, 3 and 4 mM) 
were applied as feed and H2O as release solution in the corresponding reservoirs of the in 
vitro test tool. The 10-day release profile of toremifene through the Ti/SiO2 disks is shown in 
figure 5. A lag phase, during which no toremifene release could be detected, of 1-4 days was 
observed for 2-4 mM toremifene feed solutions. After this lag phase, toremifene release 
increased during several days, reaching a maximum release of on average 0.5, 1.4 and 3.1 
nmol per 24 h (or 3, 9 and 17 μM, respectively) for increasing feed concentrations. More 
toremifene release was observed for higher feed concentrations at all time points (figure 5). 
The last measurement of release concentrations was performed after 10 days, demonstrating a 
continuous release of toremifene through the Ti/SiO2 disk over a time period of at least 6-9 
days (for feed concentrations of 2-4 mM) after passing the lag phase (figure 5). 
Provided that the release of methylene blue and toremifene is governed by Fickian diffusion, 
an estimate of the diffusivities can be calculated by adopting Fick’s first law for a disk shaped 
material with channels perpendicular to the disk surface. Taking into account the measured 
release concentrations and dimensions of the release system (note that the macropores which 
contain the SiO2 phase only take up 30% of the total surface area of the disks), the diffusivity 
of methylene blue and toremifene in H2O through the SiO2 phase of the Ti/SiO2 disks was 
estimated to be (7.7 ± 1.7)·10
-12
 m²/s and (3.6 ± 1.2)·10
-13
 m²/s, respectively.  
 
3.3 Candida albicans biofilm inhibition studies 
After 10 days of toremifene release through the Ti/SiO2 disks in the above described 
experiments, C. albicans biofilms were grown on the release side of the Ti/SiO2 disk. 
Biofilms were allowed to grow for 48 h after which RPMI medium was replaced by fresh 
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RPMI followed by an additional 24 h of biofilm growth. Subsequently, biofilm mass was 
quantified using the metabolic viability dye CTB. Preliminary studies to ascertain growth of 
C. albicans biofilms on the release side of Ti/SiO2 disks with blank feed side solutions were 
performed. Biofilm formation was quantified in these control experiments by plating (colony 
forming unit determination) and metabolic staining with CTB, showing highly reproducible 
C. albicans biofilm formation (~4.10
6
 colony forming units/biofilm) on the release side of 
Ti/SiO2 disks (data not shown). Figure 6 shows the metabolic activity of C. albicans biofilm 
cells grown on top of the Ti/SiO2 disks that were placed in toremifene feed solutions with 
different concentration (3 and 4 mM).  
C. albicans biofilms grown on the release side of Ti/SiO2 disks showed significantly 
decreased metabolic activity (± 70% reduction) for both toremifene feed concentrations as 
compared to blank feed solutions. These results indicate that toremifene, released through the 
Ti/SiO2 disks, is still biologically active at the release side and is able to substantially reduce 
C. albicans biofilm formation.  
 
4. Discussion 
Medical implants, like internal prostheses and especially dental fixtures and percutaneous 
implants, are particularly susceptible to microbial infections which can lead to bone loss and 
eventually implant instability. A systemic antibiotic treatment is often insufficient to 
completely eradicate implant-associated infections due to biofilm formation at the implant 
surface [11]. Localized administration delivering a high dosage of antimicrobials directly to 
the site without exceeding the systemic toxicity level is more effective. 
Because of the high mechanical requirements, load-bearing parts in orthopedic and dental 
implants are preferentially made from biocompatible metals, such as stainless steel, cobalt 
chromium alloys and titanium or titanium-based alloys [41]. Clinical applications of local 
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drug delivery in combination with metallic bone implants are limited to the use of antibiotic-
impregnated bone cements for cemented implants. Following the present-day trend toward a 
cementless fixation based on direct bone-to-implant osseointegration, drug delivery from 
metallic implants, is mainly implemented by embedding antimicrobials into polymeric 
(polylactides and/or polyglycolides, polymethylmethacrylate) or ceramic (calcium 
phosphates, titania nanotubes) surface coatings, releasing the therapeutic agents either by 
dissolution of the excipient coating and/or diffusion through its pores [4,17,18,42]. 
Alternatively, also the covalent bonding of antibiotics directly to the implant surface has been 
investigated [18,43,44]. However, such coating based drug eluting systems tend to be fragile, 
especially when considering the high shear forces generated during implant insertion, as both 
orthopedic and dental implants rely on a press-fit action to ensure primary stability and a good 
bone-to-implant contact [43]. Moreover, therapeutic agents need to be loaded prior to 
implantation and the loading capacity is limited. Most of these coatings exhibit an initial burst 
release immediately after surgery followed by a slower, continuous – but limited in time – 
release phase [4,18]. Therefore, these types of coatings only aim at preventing the occurrence 
of early infections. Moreover, if the release drops to sub-inhibitory levels too early after 
implantation, there is a high risk of re-infection and, maybe more importantly, of resistance 
development [16,43]. 
In this work, we propose a new composite material for bone implants with a controlled-
release functionality incorporated into the Ti load-bearing matrix of the implant. An open 
porous Ti structure is used as high-strength metallic matrix incorporating mesoporous SiO2 for 
drug delivery. By a sol-gel impregnation process, the mesoporous particles are synthesized 
directly in the macropores of the Ti establishing a diffusion barrier between an internal 
reservoir (feed side) and the tissue at the implant surface (release side).  
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It is hypothesized that a stable concentration gradient in-between the refillable internal 
reservoir and the implant surface will enable a slow but sustained release over extended 
periods of time. Therefore, the envisaged macroporous Ti structure should exhibit an open 
pore structure with high interconnectivity to allow mass transport through the bulk, without 
compromising the mechanical strength and with pores small enough to retain the SiO2 sol 
during sol-gel processing. Powder metallurgy based on partial sintering of metal powders is a 
common technique to produce porous metallic biomaterials. Limiting the sintering 
temperature and time, high pore interconnectivity can be established, while the pore size can 
be tuned by optimizing the starting powder particle size [45,46]. However, because oxidation 
hinders particle bonding, pure Ti powders require a high vacuum environment as well as high 
temperature (> 1100°C) for sintering in order to obtain a good mechanical integrity [45]. To 
improve the sinterability of the powder compact, small amounts of TiH2 powder can be 
added. Hydrogen release during heat treatment (between 450 and 650°C) reduces oxide 
impurities at the powder surface and allows lowering the sintering temperature significantly 
without compromising the mechanical strength [46,47]. Moreover, the hydrogen content after 
heat treatment remains well below the accepted level of hydrogen impurity for commercially 
pure Ti grades 1 to 4 according to ASTM F67 [46]. For the current application, we selected a 
Ti powder with a broad particle size distribution up to 45 µm in combination with a small 
amount of finer sized TiH2. The larger Ti particles define the main pore size up to 10-20 µm, 
while the finer fraction provides a good interparticle connection. Nevertheless, the pore 
structure is fully interconnected as the open porosity equals the total porosity. The pore 
window size distribution is relatively small around 1-2 µm,  but is still relevant for implant 
applications as we have recently shown that bone ingrowth for pore window sizes between 1-
10 µm is still possible [48].  
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SiO2 was successfully incorporated in the bulk of the porous Ti structure while preserving its 
mesoporous features. A high filling degree with limited residual macroporosity is observed, 
effectively establishing a mesoporous barrier within the core of the porous Ti. This is 
particularly confirmed by the controlled release of the antibiofilm compound toremifene. A 
highly reproducible permeation of toremifene from a feed solution through the pores of 
Ti/SiO2 disks was recorded without an initially high release rate (burst release). Estimation of 
the toremifene and methylene blue diffusivities through the SiO2 phase showed that the 
diffusion regime does not correspond to molecular (D ~ 10
-5
 m²/s) or Knudsen diffusion (D ~ 
10
-5
 – 10-9 m²/s) in mesoporous materials, but relates to configurational diffusion, the 
predominant regime when the pore size is comparable to the kinetic diameter of the molecule 
[22,49]. As such, toremifene with an estimated molecular size of ~15 x 20 x 3 Ǻ and 
molecular weight of 405.96 g/mol travels more slowly through the 7 nm pores of the 
mesoporous SiO2 than the smaller methylene blue (~ 14 x 6 x 4 Ǻ), as implied by the lower 
diffusivity of toremifene. This indicates that further fine-tuning of the mesopore 
characteristics of the SiO2 allows establishing a tailored release for molecules of various sizes.  
Moreover, the cumulative toremifene elution did not level off during the observation period 
presenting a sustained release over 9 days for a 4 mM feed solution. The 10-day release 
profile showed that the toremifene release concentrations scale with the feed concentrations, 
making the released amount of bioactive compound adaptable. Additionally, the lag phase 
(period of time in which no toremifene could be detected in the release sample) was shorter 
for higher feed concentrations. For in vivo implant applications, this might be more favorable, 
although this phase can be passed through before implantation if lower release concentrations 
are desired. These results differentiate the current work from previous studies which are 
predominantly characterized by either a burst release or premature depletion of the compound 
[18,27–29]. 
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Our results indicate that toremifene, continuously released through the Ti/SiO2 disks during 
10 days, is still biologically active and able to reduce C. albicans biofilm formation on the 
Ti/SiO2 surface. The two different feed concentrations (3 and 4 mM), resulting in release 
concentrations of 6-10 μM after 10 days, were both effective in inhibiting C. albicans biofilm 
formation (70% reduction of metabolic activity). Delattin and coworkers [30] report on the 
cytotoxicity of toremifene on osteoblast-like cells (MG63 cells). It was shown that 25-50 μM 
toremifene was toxic for this type of cells, whereas results obtained with lower toremifene 
concentrations showed no cytotoxicity or inhibition of growth until day 7 post-addition [30]. 
On average, even the highest release concentration that was measured in this study (17 ± 2 
μM) stayed below these values, affirming that our conditions are clinically relevant. 
As the development or treatment of a disease (such as peri-implantitis on dental implants) 
often involves multiple steps (such as prevention of tissue destruction, inhibition of 
inflammation and support of tissue regeneration), which are best targeted by different types of 
drugs, sequential administration of different compounds is frequently recommended. 
However, this goal has not been pursued very often in the design of novel implant materials 
before. Most implant materials suitable for controlled release of a medical drug are preloaded, 
releasing only one compound until depletion. Hence, they focus mainly on antimicrobial or 
antibiofilm activity [18,50]. Sundararaj et al. [51] recently designed a multiple drug delivery 
system directed at periodontitis, which sequentially releases compounds that eliminate the 
infection, inhibit inflammation, prevent tissue destruction and aid in bone regeneration, which 
might be suitable for treatment of peri-implantitis as well. In this respect, it would be 
interesting to further investigate whether implants manufactured from our innovative material 
and containing a refillable internal reservoir are suitable to sequentially release different types 
of compounds. 
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5. Conclusion 
By combining titanium powder metallurgy with SiO2 sol-gel processing, we developed a new 
Ti/SiO2 composite material, suitable for the construction of load-bearing bone implants with a 
controlled drug release feature. Ti substrates with fully interconnected macroporosity were 
injected with a SiO2 sol so that after calcination a mesoporous barrier was established within 
the bulk of the Ti. In vitro release of the antibiofilm compound toremifene displayed a 
continuous elution over a time span of at least 9 days, without a burst release effect. Applying 
different feed concentrations allowed fine-tuning the desired release concentrations with high 
reproducibility. Furthermore, toremifene release was governed by configurational diffusion 
through the mesopores, suggesting our design allows to additionally tailor the release kinetics 
of various molecules by adjusting the mesoporous structure. Finally, toremifene, released 
through the pores of the Ti/SiO2 material, substantially reduced C. albicans biofilm formation 
on the Ti/SiO2 surface.  
In summary, our observations support a proof-of-concept for a prolonged localized delivery of 
therapeutic compounds through the bulk of a mesoporous Ti/SiO2 composite material 
containing an internal reservoir which has the potential to control the drug release rates, 
depending on the patient’s needs.  
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Figure captions 
 
 
Figure 1: In vitro test tool based on a 12-well plate system 
(a) The permeable membrane of polystyrene cell culture inserts is replaced by the experimental porous Ti/SiO2 
disks, (b) effectively separating the well (dark blue feed compartment) from the cup (light blue release 
compartment) by a mesoporous diffusion barrier (grey Ti/SiO2) for controlled release of the compound through 
its pores (as indicated by the arrows). 
 
  
   
Figure 2: Characterization of the macroporous Ti carrier substrates 
(a-b) SEM micrographs of the Ti (grade S < 8 µm, Chemetall) and TiH2 (grade VM, Chemetall) starting powders 
and (c) a representative polished cross-section of a macroporous pure Ti structure after heat treatment together 
with (d) the pore window size distribution as measured by mercury intrusion porosimetry. 
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Figure 3: Cross-section of a Ti/SiO2 composite 
(a) SEM micrograph and associated elemental mappings for Ti, Si and O obtained by EDX at 20 kV accelerating 
voltage and 5 mm working distance and (b) SEM micrograph of the Ti/SiO2 interface at high magnification for a 
representative polished cross-section of a Ti/SiO2 composite. 
 
    
Figure 4: Characterization of the mesoporous diffusion barrier by nitrogen adsorption  
After outgassing the Ti/SiO2 composites for 12 h at 200°C, nitrogen adsorption/desorption isotherms were 
recorded at -196°C. The specific surface area and pore size distribution were determined using the BET and DFT 
method, respectively. (a) Nitrogen adsorption and desorption isotherm branches at -196°C and (b) DFT pore size 
distribution for a representative Ti/SiO2 composite after calcination. 
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Figure 5: Release profile of toremifene through Ti/SiO2 disks in the in vitro test tool 
Cumulative amount of toremifene released through Ti/SiO2 disks in the in vitro test tool for different toremifene 
feed concentrations (measured by UV spectrophotometry at 278 nm). Values are mean ± standard error of at 
least 2 independent experiments containing 4-9 repeats (n=10-16). 
 
 
Figure 6: Metabolic activity of C. albicans biofilms grown on Ti/SiO2 disks in the in vitro test tool 
Values are mean ± standard error of two experiments containing duplicate measurements (n = 4), measured by 
CTB staining. The asterisks indicate a statistically significant difference in metabolic activity (p < 0.001). 
